Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PREVENTABLE

Financiado

CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS, the lifetime risk to develop various cancers can be as high as 100%, and patients have a... ver más

31/12/2025

I3S INSTITUTO DE...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 16 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-12-02

HORIZON-HLTH-2022-CARE-08-04: Better financing models for health... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 2 años

0% 99% 100%

16 Participantes

I3S INSTITUTO DE INVESTIGAC...

2.07M€ | Lider

FUNDACIO PRIVADA INSTITUT D'...

N.D. | Participante

HOPITAL CHARLES NICOLLE

350.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2013-45836-R ANALISIS GENOMICO DEL CANCER HEREDITARIO 151K€ Cerrado

PID2019-107043RA-I00 DESCIFRANDO EL ROL DEL SEXO BIOLOGICO EN LA GENETICA DEL CAN... 143K€ Cerrado

DI-14-06995 DESARROLLO Y VALIDACIÓN DE UN PANEL DE GENES PARA EL ESTUDIO... 44K€ Cerrado

CNS2023-145149 Cáncer 200K€ Cerrado

PTA2012-8040-I CONSOLIDACIÓN DE LA COLECCIÓN DE CÁNCER HEREDITARIO PARA PRO... 36K€ Cerrado

SAF2010-20493 IMPLICACIONES DEL TIPO DE MUTACION GERMINAL EN EL PRONOSTICO... 97K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2022-12-02
Fecha Fin: 2025-12-31

Líder del proyecto

I3S INSTITUTO DE INVESTIGACAO E INOVACAO EM... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 5M€

Descripción del proyecto Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS, the lifetime risk to develop various cancers can be as high as 100%, and patients have a 50% chance of transmitting the disease to their offspring. When undiagnosed or not surveilled, many asymptomatic RTRS patients develop particularly aggressive cancers, leading to premature death, severely impacting theirs and their families’ health and wellbeing. Cancers in RTRS can be prevented and survival rates maximized if asymptomatic RTRS patients are intensively surveilled for RTRS-prone organs, cancer-prone organs are surgically removed prior to disease development, or very small cancerous or pre-cancerous lesions are removed or treated. RTRS are therefore a unique and tangible context for cancer prevention, early diagnosis and treatment with curative intent. However, risk-reduction strategies are not always prioritized in genetically diagnosed and asymptomatic RTRS patients, and most healthcare systems keep on opting for treatment of clinically expressed cancer. This occurs despite the knowledge that hospitalization has the highest weight on advanced cancer healthcare spending. It is therefore urgent to demonstrate the cost-benefit of the application of preventive measures in RTRS syndromes. The ambition of the PREVENTABLE project is to merge specialized clinical knowledge on RTRS pathways of care, real-life clinical data from RTRS patients and experiences from professionals and patients, with health economic models and social sciences approaches to estimate the cost-benefit of risk-reduction interventions in RTRS and delineate guidelines for its communication among and within clinical teams and RTRS patients. PREVENTABLE project results will be delivered to a diversity of stakeholders, including policy-makers, in order to promote the implementation of cost-effective RTRS patient-centered care in Europe.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores